Business context and reporting period
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA immunotherapies and vaccines delivered with its CELLECTRA electroporation devices. It had no approved products or product-sale revenue. This Form 10-K covers the fiscal year ended December 31, 2014; fourth-quarter figures are unaudited.
Financial results and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $10.46 million | $13.47 million |
| Research and development expense | $34.10 million | $21.37 million |
| General and administrative expense | $15.86 million | $13.64 million |
| Operating loss | $39.50 million | $19.54 million |
| Net loss attributable to Inovio | $36.12 million | $66.03 million |
| Basic / diluted loss per share | $(0.61) / $(0.64) | $(1.43) / $(1.43) |
| Cash and cash equivalents | $40.54 million | $33.72 million |
| Short-term investments | $53.08 million | $18.91 million |
Net cash used in operating activities was $29.82 million, versus $15.38 million in 2013. Net cash provided by financing was $72.46 million, including approximately $59.2 million net proceeds from a March share offering and $13.3 million from warrant and option exercises. Working capital was $84.9 million; total liabilities were $20.25 million. The filing reports no material long-term debt, but operating lease obligations totaled $13.75 million. Meaningful product gross margins are not available because the company had no product sales.
In the unaudited fourth quarter, revenue was $2.46 million and net loss attributable to Inovio was $7.41 million, compared with revenue of $1.74 million and a net loss of $15.45 million in fourth-quarter 2013.
Material changes versus the prior comparable period
- Revenue fell 22%, mainly because a substantial portion of Roche’s $10 million upfront payment had been recognized in 2013; this was partly offset by higher 2014 revenue for Roche-funded services.
- R&D expense rose 60%, reflecting Roche collaboration costs, increased staffing and compensation, research activity, and device-development services. Operating loss approximately doubled.
- Net loss narrowed substantially, primarily because 2013 included a $45.6 million loss from revaluing stock warrants; the 2014 warrant fair-value gain was comparatively small. This noncash accounting item makes net-loss comparisons less indicative of underlying operating performance.
- Cash and short-term investments increased to $93.6 million, supported by equity financing and warrant and option exercises, despite higher operating cash use.
Outlook, commentary, risks and unusual items
- Management said existing cash and short-term investments were expected to fund planned working-capital needs through the end of 2017, excluding the planned VGX-3100 Phase III trial. The company expected continued operating losses and reliance on outside financing beyond that period.
- VGX-3100 met its Phase II primary endpoint: histologic regression occurred in 49.5% of treated patients versus 30.6% of placebo patients. Management intended to advance the candidate to Phase III, targeting initiation in early 2016, subject to follow-up and regulatory alignment.
- Roche ended its prostate-cancer collaboration and license for INO-5150, with termination effective in February 2015; rights were to return to Inovio. The hepatitis B program, INO-1800, remained under collaboration, with Roche funding development. The filing says future Roche event-based payments were reduced significantly.
- Revenue was concentrated: Roche accounted for 70% and NIAID for 12% of 2014 revenue. Dependence on a small number of collaborators and government awards creates funding and revenue risk.
- Other key risks include clinical and regulatory uncertainty, manufacturing scale-up and third-party supplier dependence, competition, intellectual-property challenges, and the need for additional capital. The company cautioned that Phase II results may not predict later-stage outcomes.
- The company reported a $2.0 million expected payment from the sale of VGX Animal Health assets but recorded no receivable because collection was uncertain. The filing also reported effective disclosure controls and internal control over financial reporting, and an unqualified audit opinion.
Important facts for investors to verify
- Whether VGX-3100’s Phase II findings are confirmed in full follow-up and support a feasible, funded Phase III trial; the stated runway excludes that trial.
- How the Roche termination for INO-5150 affects future collaboration revenue, milestone opportunities, and Inovio’s own development costs, while confirming the continuing INO-1800 arrangement.
- Actual cash burn, investment liquidity, and financing needs against management’s end-of-2017 runway estimate.
- Whether revenue concentration with Roche and government funders changes, and whether the uncertain VGX Animal Health sale proceeds are collected.
- Clinical safety, efficacy, regulatory progress, and manufacturing readiness across the pipeline; all human product candidates remained investigational.